ProShare Advisors
SCPH

ProShare Advisors’s scPharmaceuticals SCPH Stock Holding History

ProShare Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,784
Closed -$28.4K – 2171
2025
Q1 		$28.4K Sell
10,784
-2,681
-20% -$8.73K ﹤0.01% 2006
2024
Q4 		$47.7K Buy
+13,465
New +$51.6K ﹤0.01% 2181

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ProShare Advisors's SCPH Position: Q2 2025 in Review

ProShare Advisors sold out of scPharmaceuticals (SCPH) in Q2 2025, closing a stake of 10,784 shares — an estimated $28.4K sold.

ProShare Advisors first reported a position in SCPH in Q4 2024 and held it in 2 quarters. The position peaked at $47.7K in Q4 2024. 97 funds tracked by Wall St. Rank hold SCPH as of Q2 2025.

  • ProShare Advisors reported no remaining scPharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,784 scPharmaceuticals shares in Q2 2025, an estimated $28.4K.
  • ProShare Advisors first reported a position in scPharmaceuticals in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's scPharmaceuticals position peaked at $47.7K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.